Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data.

about

Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data.

Item

http://www.wikidata.org/entity/Q36350526

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Characteristics and prognosis ...... an analysis of registry data.

@ast

Characteristics and prognosis ...... an analysis of registry data.

@en

type

Item

label

Characteristics and prognosis ...... an analysis of registry data.

@ast

Characteristics and prognosis ...... an analysis of registry data.

@en

prefLabel

Characteristics and prognosis ...... an analysis of registry data.

@ast

Characteristics and prognosis ...... an analysis of registry data.

@en

P1476

Characteristics and prognosis ...... an analysis of registry data.

@en

P2093

Kinki GIST Study Group

http://www.w3.org/2001/XMLSchema#string

Masaki Mori

http://www.w3.org/2001/XMLSchema#string

Masayoshi Yasui

http://www.w3.org/2001/XMLSchema#string

Toshimasa Tsujinaka

http://www.w3.org/2001/XMLSchema#string

Toshirou Nishida

http://www.w3.org/2001/XMLSchema#string

Tsuyoshi Takahashi

http://www.w3.org/2001/XMLSchema#string

Yasuo Nakashima

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group.

Gastrointestinal stromal tumors: pathology and prognosis at different sites.

Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

P31

scholarly article

P356

10.1007/S00595-017-1524-8

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28421351

http://www.w3.org/2001/XMLSchema#string